Datopotamab Deruxtecan, often abbreviated as DATO, represents the significant advancement regarding targeted cancer treatment. This novel antibody-drug conjugate combines a monoclonal antibody specifically targeting HER-2 expressing cells with the potent chemotherapeutic payload, deruxtecan. The route of action involves the antibody's capacity to b